Investigating how MYCT1 influences blood stem cell behavior
MYCT1 as a moderator for signaling between human HSC and their niche
This study is looking at how a protein called MYCT1 affects blood stem cells, which are important for making healthy blood, to help us understand how to better treat blood-related diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10795912 on NIH RePORTER |
What this research studies
This research focuses on hematopoietic stem cells (HSCs), which are crucial for producing blood cells throughout a person's life. The study aims to understand how a protein called MYCT1 regulates the behavior of these stem cells, particularly how they respond to their environment and make decisions about growth and differentiation. By using advanced techniques to manipulate MYCT1 levels in human stem cells, the researchers hope to uncover the mechanisms that maintain the stem cells' ability to self-renew and differentiate properly, which is essential for treating blood-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with hematological diseases who may benefit from advanced stem cell therapies.
Not a fit: Patients with non-hematological conditions or those who do not require stem cell interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for expanding functional blood stem cells, enhancing treatments for hematological diseases.
How similar studies have performed: Previous research has shown promising results in manipulating stem cell behavior through molecular regulation, suggesting that this approach could yield significant insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Mikkola, Hanna Katri Annikki — University of California Los Angeles
- Study coordinator: Mikkola, Hanna Katri Annikki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.